<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02426216</url>
  </required_header>
  <id_info>
    <org_study_id>201412038RINB</org_study_id>
    <nct_id>NCT02426216</nct_id>
  </id_info>
  <brief_title>Molecular Effects of a Multi-carotenoids (MCS) New Agent on Prostate Cancer Chemoprevention</brief_title>
  <official_title>Molecular Effects of a Multi-carotenoids (MCS) New Agent on Prostate Cancer Chemoprevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Health Ever Bio-Tech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is to prospectively investigate whether the chemopreventive agent, MCS, may favorably&#xD;
      alter biomarker expression, whether serum carotenoids levels are associated with biomarkers&#xD;
      levels, and whether the alterations of biomarker expression may reflect the cancer risk as&#xD;
      shown by cancer incidence at the end of the clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many epidemiological studies have shown that nutrients or elements from tomato or other&#xD;
      plants, including lycopene and multi-carotenoids, may reduce the risk of prostate cancer,&#xD;
      especially those of lethal cancer. Studies have also shown that multi-carotenoids may reduce&#xD;
      serum PSA levels in prostate cancer patients. MCS is a patented, multi-carotenoids-rich,&#xD;
      purely botanic agent. The investigators' previous Phase II and III clinical trials (US FDA&#xD;
      and TFDA, 600 subjects, studies finished, data in analysis) have shown that there were no&#xD;
      MCS-related serious adverse events (SAE). MCS may relieve urinary symptoms in men with BPH&#xD;
      and PSA was reduced in men with elevated PSA. So, the investigators are initiating a large&#xD;
      multi-center phase II randomized study (MCS-8, N=702) in Taiwan, to study if MCS can reduce&#xD;
      the risk of prostate cancer. High risk patients will be assigned to take oral daily 30, 15,&#xD;
      and 0 (placebo) mg of MCS (1:1:1). The investigators will compare the cumulative prostate&#xD;
      cancer incidence among groups and the change from baseline in serum carotenoids levels.&#xD;
&#xD;
      (MCS-8-TWN-II Clinicaltrials.gov NCT02042807)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative histologically proven prostate cancer</measure>
    <time_frame>up to 104 weeks</time_frame>
    <description>Cumulative histologically proven prostate cancer incidence at 2 years</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>Group A: Subjects who fullfil all eligibility criteria of the MCS-8 protocol and consent to enroll the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>Group B: Subjects who fullfil the definition of elevated risk for prostate cancer by the MCS-8 protocol but did not sign up for the MCS-8 study.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, urine, prostate tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who are increased risk of prostate cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        1. Subject of MCS-8 study inclusion criteria of MCS-8 study&#xD;
&#xD;
          1. high-risk subjects of prostate cancer.&#xD;
&#xD;
          2. Male subject with age from 50 to 75 years old.&#xD;
&#xD;
          3. No active urinary tract infection (UTI) or bacterial prostatitis.&#xD;
&#xD;
          4. Subject is able to understand and willing to comply with the study procedures and has&#xD;
             signed the informed consent form (ICF).&#xD;
&#xD;
        exclusion criteria of MCS-8 study&#xD;
&#xD;
          1. Subjects' elevated PSA is deemed by the investigators solely to inflammation or&#xD;
             infection of the prostate.&#xD;
&#xD;
          2. Subjects who are or will be taking long-term hormonal agents that may affect the&#xD;
             normal physiology of sex hormone function.&#xD;
&#xD;
          3. Subjects with a PSA &gt; 10.0 ng/ml.&#xD;
&#xD;
          4. Subjects with a history of prostate cancer.&#xD;
&#xD;
          5. Subjects are currently taking or planning to take oral bile acid sequestrants.&#xD;
&#xD;
          6. Subjects have malabsorption conditions.&#xD;
&#xD;
          7. Subject participated in another investigational agent study in the past 30 days or is&#xD;
             planning to do so during the study period.&#xD;
&#xD;
          8. Subjects are considered ineligible for the study as judged by the investigator.&#xD;
&#xD;
          9. Other malignancies except non-melanoma skin cancer.&#xD;
&#xD;
        2. Subject is eligible for MCS-8 study but did not sign up for the MCS-8 study.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Subject is not able to understand and willing to comply with the study procedures and has&#xD;
        not signed the informed consent form (ICF).&#xD;
&#xD;
        Note: (MCS-8-TWN-II Clinicaltrials.gov NCT02042807)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yeong-Shiau Pu</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yeong-Shiau Pu</last_name>
    <phone>02-23123456</phone>
    <phone_ext>65249</phone_ext>
    <email>yspu@ntu.edu.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Health Ever Bio-Tech Co., Ltd.</last_name>
    <phone>+886-25788621</phone>
    <email>heb@hebiotech.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <state>Test2</state>
        <zip>test3</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yeong-Shiau Pu</last_name>
      <phone>02-23123456</phone>
      <phone_ext>65249</phone_ext>
      <email>yspu@ntu.edu.tw</email>
    </contact>
    <contact_backup>
      <last_name>Helth Ever Bio-Tech Co., Ltd.</last_name>
      <phone>+886-25788621</phone>
      <email>heb@hebbiotech.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>April 9, 2015</study_first_submitted>
  <study_first_submitted_qc>April 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2015</study_first_posted>
  <last_update_submitted>October 25, 2015</last_update_submitted>
  <last_update_submitted_qc>October 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>chemoprevention</keyword>
  <keyword>biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

